SAB Biotherapeutics (SABS, Financial) received a reaffirmed "Buy" rating from Chardan Capital, as noted in the latest analyst update. The analyst, Keay Nakae, confirmed that the current price target remains unchanged at $20.00 USD.
The analysis, dated May 15, 2025, highlights continued confidence in SAB Biotherapeutics (SABS, Financial) despite current market conditions. Both the previous and current price targets are aligned at $20.00 USD, indicating a consistent outlook from the Chardan Capital team.
For investors interested in SAB Biotherapeutics (SABS, Financial), this maintained rating and steady price target serve as key indicators of Chardan Capital's positive market sentiment towards the biotherapeutics company.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 4 analysts, the average target price for SAB Biotherapeutics Inc (SABS, Financial) is $9.25 with a high estimate of $12.00 and a low estimate of $7.00. The average target implies an upside of 371.94% from the current price of $1.96. More detailed estimate data can be found on the SAB Biotherapeutics Inc (SABS) Forecast page.
Based on the consensus recommendation from 4 brokerage firms, SAB Biotherapeutics Inc's (SABS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
